GLOBAL BRIDGE CONSULTING
DIVERSITY, EQUITY AND INCLUSION
The COVID-19 pandemic served as a pivotal moment in our community engagement efforts, bringing to light significant health disparities and perceptions surrounding vaccination uptake. In response, we have forged meaningful partnerships with community organizations and healthcare professionals of African descent both in the United States and Africa. These collaborations have enabled us to better understand and address the unique needs and concerns of our communities, fostering trust, and promoting healthcare programs and vaccine acceptance on both continents.
We specialize in assisting pharmaceutical companies in crafting robust Diversity, Equity, and Inclusion (DEI) strategic plans. From clinical trials to access to therapy and drug safety reporting.
PROFESSIONAL AND
CLINICAL SUPPORT
Over the past decade, the healthcare landscape has evolved significantly, witnessing a surge in the utilization of biologics and other intricate therapies. Navigating this complex terrain has become increasingly challenging, accentuated by the imperative for diversity in both clinical and post-marketing data reporting.
Through our extensive network of diverse healthcare professionals, patients, governments, and service providers, we are well-positioned to facilitate connections and execute various crucial functions, including:
- Medication therapy management (MTM)
- Comprehensive medication review (CMR)
- Drugs authentication and quality checks.
- Complex diseases state management (DSM)
- Pharmaceutical auditing (GDP, GCP and GVP)
- Pharmacovigilance and Drug Safety.
- Clinical Trials sourcing and consulting.
GLOBAL AND PUBLIC HEALTH
With a substantial presence across Africa and a diverse team boasting a wide range of expertise, GLOBAL BRIDGE Pharmaceutical has forged strategic partnerships with experts and organizations to address pharmaceutical supply chain and healthcare challenges prevalent in developing countries. Many of these collaborative endeavors receive sponsorship from esteemed entities such as the United States government, the United States Agency for International Development (USAID), the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR), and various public and private foundations.
Our core strengths include:
- Access to medicines and vaccines programs.
- Access to medicines and vaccines programs.
- Pharmacovigilance and drug safety (PV/DS)
- Healthcare management and IT solutions.
- Maternal and infant mortality projects.
- Health systems strengthening.
- Manufacturing, procurement, logistics and governance.
- Pharma project management and auditing.
GOVERNMENT AND PRIVATE ENTITIES
GLOBAL BRIDGE Pharmaceutical proudly holds certifications as a Minority Business Entity (MBE) and is registered with the National Minority Supplier Diversity Council (NMSDC), along with being listed in the System for Award Management (SAM). These credentials authorize us to conduct business with a wide spectrum of partners, including local, state, and federal government agencies, as well as privately-owned entities.
We directly engage with these agencies, leveraging our capabilities to deliver products and services that meet their specific needs and requirements.
We also collaborate with other partners or prime contractors as a subcontractor to extend our reach and capabilities.
PROFESSIONAL SUPPORT
At Global Bridge, we understand the importance of having access to up-to-date guidelines on drug therapy and medical information in your practice or hospital system. Utilizing data and resources available in the United States, we can collaborate with the pharmacy and therapeutics committee (PTC) of your hospital or organization to develop a drug formulary based on the most recent guidelines.
We help our partners participate in training and workshops in the United States that fit their learning goals. In doing so, we equip them for world-class health-care delivery.
DRUG QUALITY CONTROL
Counterfeit and fake medicines are a growing trend especially in less regulated markets. In developing countries, the risk of getting caught and penalized for producing or selling fake medicines is low due to less regulation and oversight by authorities. Hundred of thousands of patients die every year from fake or counterfeit medicines.
Despite the emergence of new technology and on site quality control devices, there are still many limitations to the drugs that can be analyzed as well as the result that these services provide with regards to qualitative and quantitative analysis of drug samples.
Our partnership with reputable USFDA approved analytical laboratories enable us to test the authenticity of the drugs you market or dispense. We serve pharmacies, hospitals, wholesalers, governments and international health organizations.
Contact us to learn more about our analytical services!